Reference number(s)
7611-H

Specialty Quantity Limit
Etcamah

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Etcamah	camizestrant

Program Description

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

Covered Quantities

Medication	Standard Limit	Exception Limit
Etcamah (camizestrant) 75 mg tablets	28 tablets per 28 days	56 tablets per 28 days

FDA-Recommended Dosing

Standard dose: 75 mg once daily

Concomitant Use of Moderate CYP3A Inducers

If concomitant use with moderate CYP3A inducers is unavoidable, increase the dose to 150 mg orally once daily for patients who are receiving Etcamah in combination with abemaciclib or palbociclib.

© 2026 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

References

1. Etcamah [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2026.

© 2026 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.